OGN News and Press, Organon & Co. From 11/30/23

2023-11-30 02:52:19 ET Summary Organon is a global healthcare company focused on women's health, with a diverse portfolio of prescription therapies and medical devices. OGN stock has been on a downward trend due to declining sales and excessive debt on the balance sheet. Despi...

2023-11-29 12:45:25 ET Organon & Co (OGN) Piper Sandler 35th Annual Healthcare Conference November 29, 2023 11:00 AM ET Company Participants Kevin Ali - Chief Executive Officer Matthew Walsh - Chief Financial Officer Conference Call Participants David...

2023-11-21 13:48:38 ET Summary VTRS reported Q3-2023 earnings in line with estimates, with total sales down 3.3%. Adjusted EBITDA fell again, and new product launches are not delivering the same margins as the old business. We look at the progress made since its listing and te...

2023-11-21 09:53:36 ET A dividend yield can tell you a lot about a payout. Not only does it tell you how much you could be collecting in dividend income, but it can give you an indication of investor sentiment, and whether the stock struggles or is doing well. An excessively high yield, for...

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference ...

2023-11-08 05:28:37 ET More on Organon Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace Organon & Co (OGN) Q3 2023 Earnings Call Transcript Organon: The Federal Reserve Black Swan (Rating Upgrade) Goldman downgrades Organon following...

sBLA based on Phase 4 study which assessed pharmacokinetic similarity between two treatment groups: multi-switching group alternating between Humira and high-concentration HADLIMA vs. Humira-continued group Filing acceptance reinforces Samsung Bioepis and Organon’s commitment to pr...

2023-11-07 13:04:38 ET Summary Organon & Co. reported its Q3 earnings, last week, which revealed underperformance in its Women's Health division and struggles in its biosimilars division. The company's debt position remains high, with net debt standing at over $8 billion. ...

2023-11-03 10:42:01 ET Organon & Co ( NYSE: OGN ) has been downgraded by Goldman Sachs from Buy to Neutral after the Merck spinoff fell short of both top and bottom line expectations in its latest Q3 report . Revenue in women's health, Organon's biggest unit, fell 8% Y/Y...

2023-11-03 00:55:40 ET Summary SPDR S&P 600 Small Cap Value ETF is invested in over 400 small caps with a tilt to value over growth. It is well-diversified across sectors and holdings. The sector breakdown, valuation ratios and historical performance are not much different...